Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | F2R | P25116 | 15/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1729019 | 0.89 | KDM4E (0.39) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1729016 | 0.89 | KDM4E (0.39) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1731712 | 0.87 | KDM4E (0.41) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL1730868 | 0.84 | KDM4E (0.46) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL1730560 | 0.83 | KDM4E (0.48) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1732049 | 0.83 | KDM4E (0.41) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1731715 | 0.82 | KDM4E (0.42) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL5484091 | 0.82 | KDM4E (0.47) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL1729189 | 0.81 | KDM4E (0.48) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL1729360 | 0.81 | KDM4E (0.58) | KDM4EMAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | KDM4E 3161/4885MAPT 3483/4885RAB9A 429/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | KDM4E 3132/4885MAPT 3440/4885RAB9A 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.